8
|
Mani NL, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm DL. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In breast cancer, elevated tumor infiltrating lymphocytes (TILs) is associated with PD-L1 expression, hormone receptors negativity, and better outcome. The presence of numerous CD8+ cytotoxic T cells in pre-treatment specimens is associated with clinical benefit from PD-1 axis blockade in melanoma and lung cancer, suggesting its predictive value. Despite recent efforts to standardize the pathologist evaluation of TILs in breast cancer, objective determination of lymphocyte subpopulations and their distribution/uniformity within tumor tissues remains largely unexplored. Here, we simultaneously measured diverse TIL subpopulations using quantitative immunofluorescence (QIF) in different areas of breast tumors to determine the heterogeneity of TILs and its possible impact for use as biomarker.
Methods: Using a multiplexed QIF-based assay for simultaneous detection of DAPI (all cells), Cytokeratin (epithelial cells, M3515-DAKO), CD3 (T lymphocytes, E272--Novus), CD8 (cytotoxic T cells, C8/144B--DAKO), and CD20 (B cells, clone L26-DAKO), we measured the levels of TIL subpopulations in whole tissue section slides of 3 tumor cores obtained from different areas of 31 breast carcinomas. The levels of the markers were measured using the AQUA method of QIF and the heterogeneity was studied using numerical correlations of log2 transformed scores and variance component analysis with linear mixed effects (LME). The concordance (kappa index [κ]) between binarized scores obtained measuring 1 vs 3 cores of the same tumor was also evaluated.
Results: As expected, we found a positive correlation between CD3 and CD8 levels across all patients (Pearson correlation coefficient [CC]=0.827). The levels of CD3 and CD8 showed weaker association with CD20 signal (CC=0.446 and 0.363, respectively). For all the TIL markers, the intra-tumor variation was higher than the inter-tumor differences with intraclass correlation coefficients (ICC) of 0.411 for CD3, 0.324 for CD8, and 0.252 for CD20. In the variance component analysis, 66-69% of the variance was attributable to signal differences between areas of the same tumor core and 30-33% was due to differences between cores from different areas. Consistent with this and using the median score as cutpoint to stratify cases in high/low marker levels, the concordance of measuring TILs in 1 vs 3 cores of the same tumor was κ=0.705 for CD3, κ=0.655 for CD8, and κ=0.603 for CD20.
Conclusion: Objective measurement of TIL markers indicates that T and B lymphocytes show heterogeneity in breast cancer. The tumor variation of the markers is driven predominantly by differences within the same tumor core. The data from our study suggests that although a single core biopsy of tumors provides considerable information regarding the degree of lymphocyte infiltration in breast cancer patients, caution should be taken when using this as a clinical biomarker.
Citation Format: Mani NL, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm DL. Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-07-09.
Collapse
Affiliation(s)
- NL Mani
- Yale University School of Medicine, New Haven, CT
| | - K Schalper
- Yale University School of Medicine, New Haven, CT
| | - C Hatzis
- Yale University School of Medicine, New Haven, CT
| | - A Chagpar
- Yale University School of Medicine, New Haven, CT
| | - L Pusztai
- Yale University School of Medicine, New Haven, CT
| | - DL Rimm
- Yale University School of Medicine, New Haven, CT
| |
Collapse
|
9
|
Rimm DL, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Epidermal Growth Factor Receptor (EGFR, HER1) is known to heterodimerize with HER2 and may modulate the effectiveness of trastuzumab or lapatinib. Historically, it has been difficult to measure, but recently we reported a new, standardized, quantitative immunofluorescence assay and a novel EGFR antibody which showed that high levels of EGFR were associated with decreased benefit in the concurrent arm of the North Central Cancer Treatment Group (NCCTG/Alliance) N9831 trial (Rimm et al, SABCS 2012). Here we assess its value in the neo-adjuvant setting in the NeoALTTO trial.
Methods: NeoALTTO randomized 455 breast cancer patients to neoadjuvant trastuzumab, lapatinib or both and showed benefit in both single anti-HER2 therapy arms, and the combination therapy showing about twice as much benefit as either single drug arm. We used the previously described AQUA method of quantitative immunofluorescence to measure EGFR levels using the D38B1 antibody on between 4 and 140 fields of view per slide on 353 specimens. The averaged EGFR score was standardized to the absolute concentration using cell lines and western blots and the 13 ng/ug total protein established in the N9831 trial was tested to determine predictive value for pathological complete response (pCR) defined as ypT0/is.
Results: In NeoALTTO, 19% of the patients had EGFR levels above 13 ng/ug, compared to 16% in NCCTG N9831. The pCR rate was 35.3% in the patients with low EGFR, compared with 29.8% for high EGFR but this difference was not statistically significant. However, when adjusted for treatment and hormone receptor (HR) status, high EGFR is statistically significantly associated with lower response rate(p = 0.038). Continuous analysis measures were not significant. The effect on overall response at 6 weeks was also weakly significant when adjusting for treatment and HR status (p = 0.06). Surprisingly, for HR negative patients in the lapatinib only arm, the pCR rate in the low EGFR group was 47.2% compared with 16.0% in the high group. While this difference is statistically significant (p = 0.014), it should be interpreted cautiously because of the small numbers of patients and the multiple tests performed.
Conclusions: High expression of EGFR by the AQUA platform appears to be associated with decreased pCR rate from HER2 targeted therapy in the neoadjuvant setting. This observation is consistent with NCCTG N9831. Although underpowered, high EGFR levels predicted decreased pCR rate from lapatinib, the opposite of that anticipated for this small molecule dual EGFR/HER2 inhibitor. Further studies are required to determine the clinical utility of this assay and the biological mechanisms underlying these observations.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-09.
Collapse
Affiliation(s)
- DL Rimm
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - E Holmes
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - K Schalper
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - I Bradbury
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - E Zarrella
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - C Ellis
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - J Baselga
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - H Eidtmann
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - M Piccart
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - N Harbeck
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - L Pusztai
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| | - E Perez
- Yale University School of Medicine, New Haven, CT; Frontier Science, Scotland, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Christian Albrechts University of Kiel, Keil, Germany; Jules Bordet Institute, Brussels, Belgium; University of Munich, Munich, Germany; Mayo Clinic, Jacksonville, FL; Glaxo Smith Kline
| |
Collapse
|
10
|
Wimberly H, Schalper K, Chen L, Velcheti V, Pusztai L, Rimm D. Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Programmed death ligand 1 (PD-L1) and its receptor, PD1, are involved in limiting immune response. In the context of cancer, tumor cells expressing PD-L1 can suppress the immune response of PD1-expressing tumor infiltrating lymphocytes (TILs). Disruption of this pathway with antibodies to either the ligand or the receptor has shown promise in the treatment of non small cell lung cancer, melanoma and renal cell cancer. Here we investigate the pathway in breast cancer.
METHODS: PD-L1 protein expression was assessed on two Yale TMA breast cancer cohorts with two-fold redundancy by quantitative immunofluorescence (QIF) using AQUA technology. Cohort 1 (YTMA201) consists of 400 patients with has extensive follow-up and adjuvant treatment information. Cohort 2 (YTMA128) consists of 245 patients with limited follow-up and no treatment information. The PD-L1 antibody (Lieping Chen, clone 5H1) has been previously validated for specificity and reproducibility using transfected cell models. TILs were assessed by a pathologist for each cohort using a score from 0-3 based on the amount of TILs within the spot. AQUA scores for PD-L1 were used as a continuous variable and also cut at the median for outcome analysis.
RESULTS: PD-L1 protein is positively correlated with TILs (p<0.0001 on cohort 1 and p = 0.0072 on cohort 2) and inversely correlated with estrogen receptor status (p<0.0001 on cohort 1 and p = 0.0188 on cohort 2) on both breast cancer cohorts examined (total n = 594). On cohort 1, PD-L1 protein expression is a marker of good prognosis as a continuous variable (p = 0.0271) as well as when cut at the median (p = 0.0151), particularly in the estrogen receptor positive subset of patients.
CONCLUSIONS: PD-L1 expression in breast cancer is positively associated with TILs and inversely associated with estrogen receptor status on two independent breast cancer cohorts. PD-L1 protein expression shows prognostic value in breast cancer patients, particularly the ER positive subset of patients. Further assessment of PD-1 axis marker expression may be valuable as the associated therapeutics are being tested in breast cancer patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-10-02.
Collapse
Affiliation(s)
- H Wimberly
- Yale University School of Medicine, New Haven, CT
| | - K Schalper
- Yale University School of Medicine, New Haven, CT
| | - L Chen
- Yale University School of Medicine, New Haven, CT
| | - V Velcheti
- Yale University School of Medicine, New Haven, CT
| | - L Pusztai
- Yale University School of Medicine, New Haven, CT
| | - D Rimm
- Yale University School of Medicine, New Haven, CT
| |
Collapse
|